IP Library Granted Patent US 9,629,809
Granted Patent B2
US 9,629,809 · App. 13/714,768 · Granted Apr 25, 2017

High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,629,809
App. No.
13/714,768
Granted
Apr 25, 2017
Kind
B2
Abstract

Disclosed is a method for the preparation of easily-swallowed, reliably-dosed, aesthetically-improved tablets of sodium ibuprofen dihydrate, the method comprising the formation of the tablets with punches or presses comprising contact surfaces which are chrome or chrome-plated.

Claims (16)

1. A process for forming tablets of sodium ibuprofen dihydrate, said process comprising forming tablets in a rotary tablet press comprising chrome contact surfaces, and punches having a punch speed, from granules of sodium ibuprofen dihydrate, the granules having been formed by a process comprising the steps of

bringing together in a low shear, high shear or fluidized-bed granulator components comprised of (i) 80-90 parts by weight on a dry basis of sodium ibuprofen dihydrate, (ii) 1 to 4 parts by weight on a dry basis of sodium carbonate, (iii) 1 to 10 parts by weight on a dry basis of non-crosslinked polyvinylpyrrolidone, and (iv) 8 to 12 parts by weight of water based on the total weight of (i), (ii), (iii), and (iv) to form a wet mixture;

granulating said wet mixture by low shear, high shear or fluidized-bed granulation to form wet granules;

drying wet granules to form dried granules having a moisture content in the range of about 12.5 to 15 wt % as determinable by measurement of weight loss at 110° C.; and

removing by sieving dried granules having a particle size greater than 16 mesh, said process of forming tablets in a press comprising a precompression force and a main compression force, wherein no punch coating occurs during the tablet-forming process.

2. A process as in claim 1 wherein the main compression force is in the range of 10 to 20 kilonewtons.

3. A process as in claim 2 wherein the main compression force is in the range of about 12 to about 16 kilonewtons.

4. A process as in claim 1 wherein the precompression force is in the range of about 0.8 to about 1.0 kilonewtons.

5. A process as in claim 1 wherein the contact surfaces of the punch are chrome-plated.

6. A process as in claim 1 wherein the contact surfaces of the punch are chrome.

7. A process as in claim 1 wherein the punch speed is in the range of about 5 to about 20 RPM.

8. A process as in claim 1 wherein the press comprises a 10-station rotary press comprising chrome contact surfaces.

9. A process as in claim 1 , wherein the main compression force is in the range of about 12 to about 16 kilonewtons; the press comprises a 10-station rotary press comprising chrome or chrome-plated contact surfaces.

10. A process as in claim 1 , wherein said granulating takes place in a high shear granulator.

11. A tablet formed by the process of claim 1 .

12. A tablet formed by the process of claim 9 , wherein the tablet is a standard 400 mg as active round tablet.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Nov 1, 2024
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: SI GROUP, INC.; ADDIVANT USA, LLC; SI GROUP USA (USAA), LLC (F/K/A ADDIVANT USA, LLC)
Reel/Frame 069290/0057 →
SECURITY INTEREST Recorded Nov 16, 2018
From: SI GROUP, INC.; ADDIVANT USA, LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 048822/0965 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2014
From: ALBEMARLE CORPORATION
To: SI GROUP, INC.
Reel/Frame 034116/0701 →